

All sections on this page are required unless otherwise specified. Incomplete information could result in a delay of testing.

PATIENT INFORMATION				
First Name	Last Name			
Sex Assigned at Birth: Male Female Patient Karyotype (if known):	Date of Birth	(mm/dd/yy)		
Gender Identification (optional):				
Email	1			
Address				
City	State	Zip Code		
Phone (mobile preferred)	Is this patient	deceased? O Yes O No te:		

SAMPLE INFORMATION				
Date Sample Collected (mm/dd/yy) Medical Record #				
Patient has had a blood transfusion (Yes No Date of Last Transfusion:				
Patient has had an allogeneic bone marrow transplant () Yes () No				
For exome-based tests, fibroblasts are required for patients who had an allogeneic bone marrow transplant. GenomeXpress® is not a suitable test for patients who had an allogeneic				

bone marrow transplant. See www.genedx.com/specimen-requirements for details.					
	ORDERING PROVIDER ATTESTATIO	N			
Ger aut Recorder resident any test diagreein pro Ger pro and fam	signing this form, the ordering provider attests that (i) he/she autheDx to perform the testing indicated; (ii) he/she is the ordering phorized by law to order the test(s) requested; (iii) any test(s) reduction form ("TRF") are reasonable and medically necessary for attent of a disease, illness, impairment, symptom, syndrome or dults will determine the patient's medical management and treatment's condition on this date of service; (v) the patient or the individual to make decisions for the patient (collectively, the "patient or relatives", when applicable, has been supplied with information or relatives, when applicable, has been supplied with information ingunal has consented to undergo genetic testing; (vi) the full argnosis codes are indicated to the highest level of specificity; (vii) inbursement from any third party, including but not limited to federgrams if testing is covered by GeneDx and will inform the patient neDx may share contact information for the ordering provider and viders listed on the this order with third parties regarding the required in the patient of	rovider and is leasted on this Test the diagnosis or isorder; (iv) the test nent decisions of this idual/family member t"), in addition to egarding genetic dappropriate he/she will not seek eral healthcare of the same; (viii) lother healthcare leasted genetic testing or the individual/			
	Secondary Findings Opt-out. By checking this box, I confirm that the patient does not wish to receive ACMG secondary findings. (Full Exome Sequencing and Genome Sequencing Tests ONLY; not for Xpanded® or Slice tests).				
	New York Retention Opt-In. By checking this box, I confirm that the patient is a New York State resident who gives permission for GeneDx to retain any remaining sample longer than 60 days after testing has been completed.				
	Patient Research Opt-Out. By checking this box, I confirm that the patient wishes to opt out of being contacted for research studies.				
	Health Information Exchange Opt-in. Check this box if your patient resides in CA, FL, MA, NV, NY, RI, and VT and wishes to opt-in to having their information shared for Health Information Exchange participation.				
	☐ Health Information Exchange Opt-out. Check this box if your patient resides in any other US state or territory and wishes to opt-out of participation in Health Information Exchange.				
Sign	ature of Ordering Provider	Date			

GeneDx Account Number	Account Name	е
Phone	Fax	
Address		
City	State	Zip Code
Ordering Provider Name	I	Role/Title
NPI	Phone Number	r
Send Report Via: ☐ Fax ☐ Email Fax #/Email:	Portal	
Additional Ordering Provider Name	(optional)	Role/Title
NPI		<u> </u>
Send Report Via: ☐ Fax ☐ Email Fax #/Email:	Portal	
SEND ADDITIONAL REPORT COPIES TO	O (optional)	
Provider Name	GeneDx Acct#	

Clinical Diagnosis		Age of Onset			
PAYMENT OPTIONS (Select One)					
O PATIENT BILL	If Patient Bill is selected, I am electing to be treate patient for this testing. I agree that neither GeneL claim to my insurance for this testing, if I have inseend an invoice to the patient listed above.	x nor I will submit a			
	Authorized Patient/Guardian Signature				

ICD-10-CM CODES

ICD-10-CM Codes to support all test(s) ordered

GeneDx Account #

Hospital/Lab Name

OINSTITUTIONAL

BILL

Place Sticker/Stamp Here



First Name	Last Name	Date of Birth

DIRECTIONS TO ORDER RAPID TESTING

- Client must email GeneDx at Xpress@genedx.com for all rapid testing cases prior to samples arriving
 Trios (proband and both biological parents) are strongly recommended for rapid tests to increase diagnostic yield and to reduce the number of variants of uncertain significance (VUS)
- Parental samples must be sent with the proband sample
- Fresh blood samples are the preferred specimen type
- Institutional or Self-Pay only

XPRESS TEST					
Please provide contact information for provisional results:					
• Contact Nan • The final, writ	ne: Phone: Email: tten report will be sent to the ordering provider.				
TEST CODE	TEST NAME				
	XomeDxXpress® (Trios recommended)				
□ 896a □ 690c	XomeDxXpress® Trio* Mitochondrial Genome Sequencing & Deletion Testing (Concurrent)‡				
□ 896e □ 690c	XomeDxXpress® Duo* Mitochondrial Genome Sequencing & Deletion Testing (Concurrent) [‡]				
□ 896b □ 690c	XomeDxXpress® Proband Mitochondrial Genome Sequencing & Deletion Testing (Concurrent)‡				
GenomeXpress® (Trios recommended)					
□ тн78а	GenomeXpress® Trio*				
☐ TH78e	GenomeXpress® Duo*				
☐ TH78b	GenomeXpress® Proband				
	NICUXpress NICUXpress				
☐ TL27	NICUXpress Panel				
	test is ordered, please fill out the <i>Family Member Samples to be Included in Testing</i> section on the next page o genome will be reported separately				

(Continue to next page)

GeneDx tests are frequently updated and improved based upon the most recent scientific evidence. The test codes, genes, and gene quantities listed on this test requisition are subject to change by GeneDx at any time. The most current test menu and list of genes included for a specific test panel may be found on our website, genedx.com. Please note that GeneDx reserves the right to modify and upgrade any ordered panel to the version currently listed on our website.



KAPID	SEQUEINC	ING IE	SI KEC	ZOISITIO	IN FORIVI		O	SI ICLX
First Name			Last	Name			Date of Birth	
			FAMILY N	MEMBER SAM	PLES TO BE IN	CLUDED IN TE	ESTING	
codes may		appropriately	y correspond	with family men	nber samples red		s FOR INCLUSION IN THE PROBAND'S TEST. e in the ordered test will impact billing, incl	
	First Name	Lo	ast Name		DOB	O Asympton	natic O Symptomatic	
Biological Mother						O At GeneDx	(Accession #:)
						O Not availa	ble O To be sent within 3 weeks	
Dialamiani	First Name	LC	ast Name		DOB	O Asympton	natic O Symptomatic	
Biological Father							(Accession #:)
	Relationship to Proban	nd				O Not availa	ble O To be sent within 3 weeks	
	First Name		ast Name		DOB			
Other Biological	l i i i i i i i i i i i i i i i i i i i		3001101110			O Asympton	· · ·	
Relative						O At GeneDx	(Accession #: ble O To be sent within 3 weeks)
						Onoravalla	Die O to be sent within 5 weeks	
				FAI	MILY HISTORY	*		
		*	This section is		or ordering a tar		sting report.	
□ No Know	vn Family History	□F	Pedigree Att	ached	☐ Adop	oted		
R	elationship	Materna	l Paternal		Relevant History			Age at Dx
1		0	0					
2		0	0					
3		0	0					
				PREVIOUS	S GENETIC TE	STING*		
		**	This section is	s not intended fo	or ordering a tarç	geted variant tes	sting report.	
Personal o	or family history of	genetic tes	sting ON	lo O Yes (If	yes, please coi	mplete all field	ds below)	
Relation to p	oatient (self, sibling, e	etc.), Genetic	Test(s) and R	esult (e.g. positiv	ve, negative, etc.)	. If relative was t	ested at GeneDx, please also provide their	accession #:
		•					·	
	relative(s) were fou y Variants of Interest			S result on prior	testing, please p	rovide details be	elow.	
Relation (s	self, sibling, etc.)	Gene	Transcrip	t# c.	/p. (SNV) or exo	n#(CNV)	Build, coordinates (CNV)	Variant of Interest‡?
1								
2								
3								
•	sequence variants: ger CNVs: gene transcript #		•					
•	Required for CNVs: gene, transcript #, exon # OR build, coordinates Abnormal karyotype, FISH, or other results:							
	, ,, , , , , , , , , , , , , , , , , , ,							
must be provi	ided <u>in the table above</u>	at the time the	test order is pla	ced. If you do not c	complete the table o	above and check o	nt(s) of interest in the report. Complete variant in ff that a previously identified variant is a variant olicable to targeted variant testing.	

(Continue to next page)



First Name Last Name Date of Birth

CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED) Relevant clinical records are required at the time of sample submission to ensure the information is included in data analysis.				
Genes of interest (limit to 10):				
Differential diagnosis:				
Pre/Perinatal History	Neurological Findings	Hearing Impairment		
☐ Cystic hygroma	☐ Abnormality of nervous system	☐ Abnormal newborn screen:		
□ Diaphragmatic hernia	□ Ataxia	☐ Conductive hearing impairment		
□ Encephalocele	Cerebral palsy	Sensorineural hearing impairment		
☐ Growth delay	Chorea	_ 3 1		
☐ Increased nuchal translucency	☐ Cortical visual impairment	Endocrino Findingo		
☐ Intrauterine growth retardation	□ Dementia '	Endocrine Findings		
□ Nonimmune hydrops fetalis	Dysarthria	☐ Delayed puberty		
□ Oligohydramnios	□ Dyskinesia	☐ Diabetes Insipidus		
□ Omphalocele	□ Dysphasia	☐ Diabetes mellitus		
□ Polyhydramnios	□ Dystonia	☐ Hyperthyroidism		
□ Prematurity GA:	□ Encephalopathy	☐ Hypophosphatemia		
□ Prolonged neonatal jaundice	□ Headaches ,	☐ Hypothyroidism		
,	☐ Hemiplegia	☐ Maturity-onset diabetes of the young		
	□ Infantile Spasms	□Rickets		
Structural Brain Abnormalies	☐ Migraines —			
☐ Abnormal myelination	□ Myoclonus	Respiratory Findings		
□ Abnormality of basal ganglia	□ Parkinsonism	☐ Asthma		
☐ Abnormality of brainstem	□ Peripheral neuropathy	☐ Bronchiectasis		
☐ Abnormality of periventricular white matter	☐ Seizures	☐ Hyperventilation		
☐ Abnormality of the corpus callosum	☐ Sensory neuropathy	☐ Hypoventilation		
□ Aplasia/hypoplasia of cerebellar vermis	□ Spasticity	☐ Pneumothorax		
□ Aplasia/hypoplasia of cerebellum	☐ Syncope	☐ Pulmonary fibrosis		
☐ Arnold Chiari malformation	☐ Tremors	☐ Respiratory insufficiency		
☐ Cerebellar atrophy	□ Vertigo	□ Respiratory insufficiency		
☐ Heterotopia (periventricular nodular				
heterotopia)	Oversia facial/Dyrana ayahiana	Hematologic or Immunologic Findings		
Holoprosencephaly	Craniofacial/Dysmorphism	☐ Allergic rhinitis		
Hydrocephalus	☐ Abnormal facial shape (dysmorphic	□ Anemia		
Leukodystrophy	features) Specify:	— ☐ Immunodeficiency		
Lissencephaly	☐ Brachycephaly	□Neutropenia		
□ Pachygyria	Cleft lip and/or palate	□ Pancytopenia		
□ Polymicrogyria	Coarse facial features	☐ Recurrent infections		
□ Ventriculomegaly	☐ Craniosynostosis	□Thrombocytopenia		
	Macrocephaly			
Developmental/Behavioral Findings	☐ Microcephaly			
· · · · · · · · · · · · · · · · · · ·	☐ Short neck	Skin/Hair Findings		
☐ Absent speech	☐ Synophrys	☐ Abnormal blistering of the skin		
Aggressive behavior		Abnormality of nail		
□ Anxiety □ Autistic behavior	Eye Defects/Vision	□ Alopecia		
	☐ Abnormality of vision	Anhidrosis		
Cognitive impairment	☐ Anophthalmia	Café-au-lait macules		
☐ Delayed speech & language development☐ Developmental regression		Coarse hair		
☐ Dysarthria	□ Coloboma	Cutis laxa		
Gait disturbance	☐ Corneal opacity	□ Eczema		
☐ Global developmental delay	☐ Ectopia lentis	☐ Hemangiomas		
☐ Hyperactivity	☐ External ophthalmoplegia	☐ Hyperextensible skin		
☐ Incoordination	□ Microphthalmia	☐ Hyperpigmentation of the skin		
	□ Myopia	☐ Hypohidrosis		
Intellectual disability		Hypopigmentation of the skin		
Learning disability	□ Nystagmus	☐ Ichthyosis		
☐ Memory impairment	□ Optic atrophy	☐ Skin rash		
☐ Sleep disturbance	□ Optic neuropathy □ Ptosis	□ Sparse hair		
☐ Stereotypy	☐ Retinal detachment	☐ Telangiectasia		
	☐ Retinitis pigmentosa	□ Vascular skin abnormality		
	☐ Strabismus	□ Velvety skin		



First Name Last Name Date of Birth

CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED) **Musculoskeletal Findings Cardiac Findings** Vascular System ☐ Abnormal connective tissue ☐ Abnormal heart morphology □ Aneurysm ☐ Arterial calcification ☐ Amyloidosis □ Abnormal form of the vertebral bodies ☐ Aortic root dilation ☐ Abnormality of the ribs □ Arterial dissection ☐ Arrhythmia ☐ Arachnodactyly ☐ Arterial tortuosity ☐ Atrial septal defect □ Arthralgia ☐ Arteriovenous malformation ☐ Arthrogryposis☐ Bruising susceptibility ☐ Bicuspid aortic valve □ Epistaxis □Lymphedema □ Bradycardia ☐ Coarctation of aorta ☐ Clinodactyly ☐ Pulmonary hypertension ☐ Dilated cardiomyopathy ☐ Decreased muscle mass ☐ Stroke □ Heterotaxy □ Ectrodactyly ☐ Hypertension □ Exercise intolerance ☐ Hypertrophic cardiomyopathy □ Fatique Cancer ☐ Mitral valve prolapse ☐ Hemihypertrophy □ Type: ☐ Noncompaction cardiomyopathy ☐ Hypertonia Location: ____ ☐ Patent ductus arteriosis ☐ Hypotonia Age of onset: ☐ Patent foramen ovale ☐ Joint hypermobility ☐ Prolonged QTc interval ☐ Muscle weakness ☐ Sudden death □ Myalgia ☐ Tetralogy of Fallot ☐ Myopathic facies ☐ Ventricular septal defect ☐ Myopathy Other Testing/Imaging ☐ Ventricular tachycardia Osteoarthritis (Please provide copy or report if possible) □ Osteopenia ☐ Echo: □ Pain □ EEG: _____ □ Pectus carinatum **Gastrointestinal Findings** ☐ Pectus excavatum ☐ EMG: □ Constipation □ Polydactyly ☐ MRI: □ Diarrhea ☐ Recurrent fractures ☐ Muscle Biopsy: ☐ Duodenal stenosis/atresia ☐ Rhabdomyolysis □ Ultrasound: ☐ Exocrine pancreatic insufficiency □ Scoliosis ☐ Failure to thrive ☐ X-rays: ☐ Short stature ☐ Feeding difficulties ☐ Skeletal dysplasia ☐ Gastroesophageal reflux Syndactyly ☐ Hepatomegaly ☐ Tall stature ☐ Inflammatory bowel disease **Additional Clinical Findings:** ☐ Intrahepatic biliary atresia Laryngomalacia **Metabolic Findings** □Nausea (Attached relevant lab reports/values) □ Pancreatitis ☐ Abnormal activity of mitochondrial ☐ Pyloric stenosis respiratory chain □ Splenomegaly ☐ Tracheoesohageal fistula ☐ Abnormal Newborn Screen: ☐ Abnormality of mitochondrial metabolism □ Vomiting ☐ Elevated CPK ☐ Elevated hepatic transaminase ☐ Hyperammonemia **Genitourinary Findings** ☐ Hyperglycemia ☐ Ambiguous genitalia ☐ Hypoammonemia ☐ Cryptorchidism ☐ Hypoglycemia Cystic renal dysplasia ☐ Increased serum pyruvate ☐ Horseshoe kidney ☐ Lactic acidosis ☐ Hydronephrosis □ Plasma AA: ☐ Hypospadias ☐ Urine OA: ☐ Inquinal hernia ☐ Micropenis □ Nephrolithiasis ☐ Polycystic kidney disease ☐ Renal agenesis ☐ Umbilical hernia



First Name Last Name Date of Birth

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

- 1. <u>Positive</u>: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
- 2. <u>Negative</u>: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
- 3. <u>Variant of Uncertain Significance (VUS)</u>: A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
- 4. <u>Unexpected Results (ACMG Secondary Findings)</u>: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care.

Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information GeneDx used to interpret my results. Healthcare providers can contact GeneDx at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents.

Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that GeneDx will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

- 1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.
- 2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
- 3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
- 4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
- 5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. GeneDx will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made.

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and GeneDx will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. GeneDx will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this de-identified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. GeneDx shares this type of information with healthcare providers, scientists, and healthcare databases. GeneDx will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. GeneDx believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.

EPILEPSY PARTNERSHIP PROGRAM PARTICIPATION

I understand that GeneDx will send de-identified test results data, excluding ACMG secondary findings, to third parties for research or commercial purposes and that GeneDx is compensated for the provision of testing services and for data sharing with third parties that is compliant with applicable law. At no time will GeneDx share any patient personally identifiable information. GeneDx may share contact information for providers listed on the Test Requisition Form with third parties.



First Name	Last Name	Date of Birth

PATIENT RECONTACT FOR RESEARCH PARTICIPATION

GeneDx may collaborate with other scientists, researchers and drug developers to advance knowledge of genetic diseases and to develop new treatments. If there are opportunities to participate in research relevant to the disorder in (my/my child's) family, GeneDx may contact my healthcare provider for research purposes, such as the development of new testing, drug development, or other treatment modalities. In some situations, such as if my healthcare provider is not available, I may be contacted directly. I can opt out of being contacted directly regarding any of the above activities by having my healthcare provider check the box for Patient Research Opt-Out. Any research that results in medical advances, including new products, tests or discoveries, may have potential commercial value and may be developed and owned by GeneDx or the collaborating researchers. If any individuals or corporations benefit financially from these studies, no compensation will be provided to (me/my child) or to (my/my child's) heirs.

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

- · Applicable only for full exome sequencing and genome sequencing tests
- Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT?

All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES?

The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS

Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified nor reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE

For insurance billing, I understand and authorize GeneDx to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to GeneDx.

I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by GeneDx as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by GeneDx on my behalf, I agree to endorse the insurance check and forward it to GeneDx within 30 days of receipt as payment towards GeneDx's claim for services rendered.

rego to p fam any	By signing this form: (i) I acknowledge that I have read or have had read to me the GeneDx Informed Consent document, and understand the information regarding genetic testing; (ii) I have had the opportunity to ask questions about the testing, the procedure, the risks, and the alternatives; (iii) I authorize GeneDx to perform genetic testing as ordered; (iv) I understand that, for tests that evaluate data from multiple family members concurrently, test results from these family members may be included in a single comprehensive report that will be made available to all tested individuals and their healthcare providers; (v) if at any time I or my provider provide an email address or mobile phone number at which I may be contacted, I consent to receiving email or text messages from GeneDx; and (vi) I understand that this consent applies to all future communications unless I request a change in writing.					
	Secondary Findings Opt-out. Check this box if you do not wish to receive AC ONLY; not for $Xpanded$ ® or Slice tests).	:MG secondary findings (Full Exome Sequencing and Ge	enome Sequencing Tests			
	New York Retention Opt-in. By checking this box, I confirm that I am a New York State resident, and I give permission for GeneDx to retain any remaining sample longer than 60 days after the completion of testing, and to be used as a de-identified sample for test development and improvement, internal validation, quality assurance, and training purposes. Otherwise, New York law requires GeneDx to destroy my sample within 60 days, and it cannot be used for test development studies.					
	Patient Research Opt-out. Check this box if you wish to opt out of being con	tacted for research studies.				
	Health Information Exchange Opt-in. Check this box if you reside in CA, FL, MA, NV, NY, RI, and VT and wish to opt-in to my health information to be shared for Health Information Exchange participation.					
	Health Information Exchange Opt-out. Check this box if you reside in any other US state or territory and wish to opt-out of participation in Health Information Exchange.					
Signo	gnature of Patient/Legal Guardian (required) Date					
Signo	ture of Relative A/Legal Guardian	Relative A Relationship to Patient	Date			
igno	nature of Relative B/Legal Guardian Relative B Relationship to Patient Date					